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LEYTER TO THE EDITOR
Prednisolone enhancement of primary endocrine anticancer treatment: a
possible anti-angiogenic effect
Sir - Rubens et al. (1988) think that prednisolone exercises
anti-oestrogenic and direct cytostatic effects in the therapy of
breast cancer. I believe that the third hypothesis should be
also mentioned: in vivo corticosteroid anti-angiogenesis.
Ever since Sakamoto & Tanaka (1988) documented the in
vitro anti-angiogenic effect of corticosteroids alone and its
enhancement by added heparin, in vivo corticosteroid anti-
angiogenesis in cooperation with endogenous heparin should
be taken in consideration (Beranek, 1988; Chen et al., 1988).
Rubens et al. (1988) have used prednisolone 5mg b.d., a
dose which may hardly lead to anti-angiogenesis after one or
several doses. However, this powerful steroid has a biological
half-life of 12-36 h (Luton et al., 1978) and cumulative effect
must be expected during long-term daily use.
Malignant tumours are angiogenesis-dependent (references
in Chen et al., 1988). Efficient anti-angiogenesis by angio-
static steroids is a most promising way of their treatment.
Unfortunately, such steroids are not yet marketed for clinical
use. For the time being, the cautious anti-angiogenesis by
glucocorticoids and low-dose heparin (Shulman, 1988) may
be a useful adjuvant to other cancer treatment modalities.
Yours etc.,
J.T. Beranek,
Service d'Anatomie et Cytologie Pathologiques,
Groupe Hospitalier Pitie-Salpetriere,
75651 Pans Cedex 13, France.
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